1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Piprot, C; Cals, L; Chaigneau, L; Demarchi, F; N'Guyen, T; Stein, U; Villanueva, C; Bréau, JL; Chouahnia, AK; Saintigny, P; Boué, F; deSaint-Hilaire, P; Guimont, I; Grossat, N; Valenza, B; Lévy, E; Médioni, J; Delbaldo, C; Grenier, J; Pouessel, D Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. (23rd October 2018) Authors: Pujol, J-L; Greillier, L; Audigier Valette, C; Moro-Sibilot, D; Uwer, L; Hureaux, J; Thiberville, L; Carmier, D; Madelaine, J; Otto, J; Gounant, V; Merle, P; Mourlanette, P; Molinier, O; Renault, P A; Mazieres, J; Antoine, M; Langlais, A; Morin, F; Souquet, P-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 220PSefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERMIONE non-interventional prospective study. (23rd October 2018) Authors: Jacquin, J-P P; Uwer, L; Savignoni, A; Ferrero, J-M; Lortholary, A; Solub, D; Attar-Rabia, H; Deblay, S; Pibre, S; Belkacemi, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 294PD_PRManagement and outcome of metastatic breast cancer in men in the national multicenter observational ESME program. (23rd October 2018) Authors: Sirieix, J; Fraisse, J; Mathoulin-Pelissier, S; Leheurteur, M; Vanlemmens, L; Jouannaud, C; Dieras, V; Levy, C; Dalenc, F; Mouret-Reynier, M-A; Petit, T; Coudert, B; Brain, E; Pistilli, B; Ferrero, J-M; Gonçalves, A; Uwer, L; Gourgou, S; Frenel, J-S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Venat-Bouvet, Laurence; Cany, Laurent; Catal... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗